• 6767 Bertner Ave, Mitchell Basic Science Research Building

    77030 Houston

    United States

  • 10660 Citations
  • 57 h-Index
19942019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where David Sanghyun Hong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Neoplasms Medicine & Life Sciences
Clinical Trials, Phase I Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Mutation Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Survival Medicine & Life Sciences
Maximum Tolerated Dose Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1994 2019

3 Citations (Scopus)

Alpha particle radium 223 dichloride in high-risk osteosarcoma: A phase i dose escalation trial

Subbiah, V., Anderson, P. M., Kairemo, K., Hess, K., Huh, W. W., Ravi, V., Daw, N. C., Somaiah, N., Ludwig, J. A., Benjamin, R. S., Chawla, S., Hong, D. S., Meric-Bernstam, F., Ravizzini, G., Kleinerman, E., Macapinlac, H. & Rohren, E., Jan 1 2019, In : Clinical Cancer Research. 25, 13, p. 3802-3810 9 p.

Research output: Contribution to journalArticle

Open Access
Alpha Particles
Radium
Osteosarcoma
Neoplasm Metastasis
Technetium Tc 99m Medronate
7 Citations (Scopus)

Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge

Parseghian, C., Loree, J. M., Morris, V. K., Liu, X., Clifton, K. K., Napolitano, S., Henry, J. T., Pereira, A. A., Vilar Sanchez, E., Johnson, B., Kee, B. K., Raghav, K. P. S., Dasari, N. V., Wu, J. Y., Garg, N., Raymond, V. M., Banks, K. C., Talasaz, A. A., Lanman, R. B., Strickler, J. H. & 4 others, Hong, D. S., Corcoran, R. B., Overman, M. J. & Kopetz, E. S., Feb 1 2019, In : Annals of Oncology. 30, 2, p. 243-249 7 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Clone Cells
Mutation
Half-Life
Colorectal Neoplasms
1 Citation (Scopus)

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors

Hong, D., Rasco, D., Veeder, M., Luke, J. J., Chandler, J., Balmanoukian, A., George, T. J., Munster, P., Berlin, J. D., Gutierrez, M., Mita, A., Wakelee, H., Samakoglu, S., Guan, S., Dimery, I., Graef, T. & Borazanci, E., Jul 1 2019, In : Oncology (Switzerland). 97, 2, p. 102-111 10 p.

Research output: Contribution to journalArticle

Open Access
Ligands
Breast Neoplasms
Non-Small Cell Lung Carcinoma
Neoplasms
Pancreatic Neoplasms
Open Access
Internet
Observational Studies
Decision Making
Cross-Sectional Studies
Physicians